Knowledge Center

Medtech Service Provider HuKui Bio raised US$5.5M for US market expansion

The medtech service provider Hukui Bio (互貴興業) announced that it has raised US$5.5 million in Series C funding, led by Yellowstone Holding AG from Switzerland, totalling US$11.8M funding to date.

HuKui Bio will collaborate with venture capital funds in the Bay area, in addition to the biomedical innovation clusters and accelerators in Europe and the US. The New Business Department and the US subsidiary in the Bay area were founded at the beginning of 2021, with the onboarding of Dr IC Jan (詹益鑑) as its Chief Strategy Officer.

“Made in China” is no longer attractive due to the U.S.-China trade war, suggesting that Taiwan’s CDMO industry for electronic medical devices is going to be more lucrative

A few days ago, I had visited Hukui Biotechnology Co., Ltd. (Hukui Bio) which was founded by John Hsuan with Michael Kuo, the current CEO. We talked about the latest development in the global electronic medical devices market and the evolution of professional electronic medical devices contract development and manufacturing organization (CDMO) industry since the US-China trade war. In recent years, Taiwan has been actively investing in the integration of biomedical and bio-ICT industries. New advancements and changes in CDMO industry will bring forth both major business opportunities and challenges, and it is worth sharing with everybody in this column.

We Are Fighting The COVID-19 Threats !

In 2020, the epidemic of COVID-19 has spread in the whole world, and COVID-19 diagnostic kit is definitely a purchasing point from the beginning. Hukui Bio has been authorized bytwo Taiwan nucleic acid diagnostic kit factories to begin providing COVID-19 diagnostic kit for Europe, ASEAN and South America markets, hoping to satisfy their local medical resources.

Cymmetrik and HUKUI Tech Work Together to Take AcuSense BioMedical Entering China Market

“Blood Leakage Detection System”, developed by AcuSense BioMedical Technology Corp. (AcuSense), is a specific medical device designed for kidney disease patient to reduce the risk of dialysis treatment. Through the cooperation with HUKUI Tech, the subsidy of Hukui Biotechnology Co., Ltd., AcuSense is going to expand its business to China. HUKUI Tech integrates product authorization, registration, production and distribution as a CDMO service. The CDMO service is a total solution provided by HUKUI Tech for those companies who are interested in marketing their new developed device. Without factory building by itself, AcuSense could speed up product launching schedule because of cost and time saving. It will help the product time on market.